IP Library › Granted Patent US 9,364,517
Granted Patent B2
US 9,364,517 · App. 14/485,315 · Granted Jun 14, 2016

Method of treatment of lymphoma with pegylated IL-10

Inventors: Martin Oft (Palo Alto, CA); Catherine Sheppard (San Francisco, CA); John Brian Mumm (Los Altos Hills, CA); Lingling Wu (Palo Alto, CA)
Assignee: Merck Sharp & Dohme Corp.
A61K38/2066A61K45/06A61K47/48215
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,364,517
App. No.
14/485,315
Granted
Jun 14, 2016
Kind
B2
Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Claims (18)

1. A method of inhibiting or reducing growth of a tumor or cancer in a subject in need thereof, the method comprising:

administering to the subject an effective amount of a pegylated interleukin-10 (PEG-IL-10), wherein the cancer or tumor is lymphoma.

2. The method of claim 1 , wherein the subject is human.

3. The method of claim 2 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).

4. The method of claim 1 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

5. The method of claim 2 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

6. The method of claim 3 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

7. The method of claim 1 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.

8. The method of claim 7 , wherein the chemotherapeutic agent is at least one of cyclophosphamide, doxorubicin, vincristine, fludarabine, carboplatin, etoposide, mitoxantrone, ifosfamide, cytarabine, cisplatin, and bleomycin.

9. A method of treating a subject suffering from lymphoma, the method comprising:

administering to the subject an effective amount of a pegylated interleukin-10 (PEG-IL-10).

10. The method of claim 9 , wherein the subject is human.

11. The method of claim 10 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).

12. The method of claim 9 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

13. The method of claim 10 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

14. The method of claims 11 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

15. The method of claim 9 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent.

16. The method of claim 15 , wherein the chemotherapeutic agent is at least one of cyclophosphamide, doxorubicin, vincristine, fludarabine, carboplatin, etoposide, mitoxantrone, ifosfamide, cytarabine, cisplatin, and bleomycin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2015
From: WU, LINGLING
To: SCHERING CORPORATION
Reel/Frame 034988/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2015
From: OFT, MARTIN; MUMM, JOHN; SHEPPARD, CATHERINE
To: SCHERING CORPORATION
Reel/Frame 034988/0248 →
CHANGE OF NAME Recorded Feb 19, 2015
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 035051/0055 →
Continuity (6)
Continuation 12976063 · Dec 22, 2010
Continuation 12463825 · May 11, 2009
Continuation 11862626 · Sep 27, 2007
Provisional Application 60915603 · May 2, 2007
Provisional Application 60848326 · Sep 28, 2006
Related Publication 20150079031A1 · Mar 19, 2015